Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2015 Feb 5;35(4):855–864. doi: 10.1161/ATVBAHA.114.304627

Fig. 1. VLN-NP mediated expression and activity of VLN in HRMEC.

Fig. 1

A: Conditioned media of VLN-NP or LN-NP were concentrated 3-fold and used for Western blotting. B: HRMEC were quantified with MTT assay at indicated durations of VLN-NP or LN-NP treatment. **p<0.01, n=6. C: HRMEC were quantified after treatment with VLN-NP or LN-NP for 72 hr in the presence of LCM or WCM. **p < 0.01, n=6. D, F: HRMEC were seeded on one side of the membrane in the insert and treated with VLN-NP or LN-NP in the presence of WCM or LCM for 12 hr. The cells migrated to the other side of the membrane were stained, and micrographs captured (D), and cells counted in five fields per insert (F). **p<0.01, n=3. E, G: HRMEC were treated with VLN-NP and LN-NP for 72 hr, seeded on Matrigel-coated plates and incubated with WCM or LCM at 37°C for 6 hr. E: Representative micrographs of tube formation (×200). G: Branching points were counted in five fields per dish. **p<0.01, n=3. H: HRMEC were transfected with a VLDLR siRNA or a control siRNA after incubation with VLN-NP or LN-NP for 48 hr for additional 24 hr. Cells were then quantified with MTT assay. **p<0.01, n=6.